Delivers real-time biopharma news and signals — powered by AI, curated for professionals.
JSR Life Sciences has announced the sale of its contract research organization (CRO) business, Crown Bioscience, to Adicon, a Chinese clinical lab service provider backed by The Carlyle Group. The deal, valued at $204 million, marks a significant shift in the landscape of oncology-focused research services.
Merck's activin blocker Winrevair continues to make waves in the pulmonary hypertension space, with new mid-stage data demonstrating significant benefits for patients with combined post- and precapillary pulmonary hypertension (CpcPH). This latest development further solidifies Winrevair's position as a leading treatment in an area with limited therapeutic options.
Genmab, the Danish pharmaceutical company, has recently made significant changes to its portfolio following the $1.8 billion acquisition of ProfoundBio in April 2024. The company has discontinued two antibody-drug conjugates (ADCs) while maintaining focus on its lead candidate, Rina-S, for ovarian and endometrial cancers.
Nxera Pharma, formerly known as Sosei Group, has unveiled a comprehensive restructuring plan aimed at enhancing profitability and refocusing its research and development efforts. The Japanese pharmaceutical company will reduce its workforce by 15% and streamline its executive team as part of a strategic initiative to meet its 2030 growth and revenue targets.
Jazz Pharmaceuticals and Zymeworks have announced groundbreaking results from their Phase III HERIZON-GEA-01 study, evaluating the HER2 bispecific antibody Ziihera in patients with gastroesophageal adenocarcinoma (GEA). The study's positive outcomes are set to reshape treatment paradigms in gastric cancer and pave the way for regulatory submissions.
Roche has announced positive results from a phase 3 trial of its oral selective estrogen receptor degrader (SERD) giredestrant, potentially positioning the drug for use in the adjuvant setting for breast cancer treatment. The success of the lidERA trial marks a significant advancement in the competitive SERD market and could offer new hope for patients with early-stage breast cancer.
Zymeworks, a Canadian biotech company, has announced a strategic shift towards a royalty-driven business model, marking a significant change in its approach to drug development and commercialization. This decision comes on the heels of positive late-stage trial results for its cancer drug Ziihera, developed in partnership with Jazz Pharmaceuticals.
Cornerstone Robotics, a Hong Kong-based surgical robotics company, has raised approximately $200 million in its latest funding round to boost the global commercialization of its Sentire Endoscopic Surgical System. This significant investment comes just 11 months after the company's previous $70 million Series C round, highlighting rapid growth and investor confidence in the emerging player in the robotic surgery market.
The rapid growth of the radiopharmaceutical sector is putting unprecedented pressure on a unique and highly regulated supply chain, as major pharmaceutical companies invest billions in this promising cancer treatment modality. Recent developments highlight both the potential and challenges of bringing these innovative therapies to patients.
Clairity, a leading innovator in medical artificial intelligence, has secured $43 million in Series B funding to accelerate the commercialization of its groundbreaking breast cancer risk prediction platform. The investment, led by ACE Global Equity and Santé Ventures, marks a significant milestone in the company's mission to revolutionize early cancer detection and personalized screening protocols.
Johnson & Johnson (J&J) has announced a $3.05 billion cash acquisition of Halda Therapeutics, a move that significantly strengthens its oncology portfolio and advances its ambitious goal of reaching $50 billion in cancer sales by 2030. The deal, expected to close within the next few months, centers on Halda's innovative "hold and kill" technology platform and its promising prostate cancer candidate.
Eli Lilly has announced a significant partnership with South Korean biotech ABL Bio, further bolstering its pipeline and expanding its reach into bispecific antibody development. The deal, valued at up to $2.6 billion, marks Lilly's latest move in a series of strategic investments aimed at enhancing its drug discovery capabilities.
